Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447952 | 1.00 | CHRNA7 (0.80) | CHRNA7 | |
| Hydrochloric Acid SCHEMBL15663070 | 0.99 | CHRNA7 (0.79) | CHRNA7 | |
| SCHEMBL14006127 | 0.90 | CHRNA7 (0.98) | CHRNA7 | |
| SCHEMBL14005997 | 0.89 | CHRNA7 (1.00) | CHRNA7 | |
| SCHEMBL14005985 | 0.88 | CHRNA7 (0.82) | CHRNA7 | |
| SCHEMBL14006077 | 0.85 | CHRNA7 (0.81) | CHRNA7 | |
| SCHEMBL14005980 | 0.85 | CHRNA7 (0.77) | CHRNA7 | |
| SCHEMBL14006109 | 0.82 | KDR (0.61) | — | |
| SCHEMBL23540740 | 0.79 | LMNA (0.71) | — | |
| SCHEMBL30043036 | 0.79 | LMNA (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | UNIV CALIFORNIA (US) | 2023-03-30 | — | — | US | claimed |
| EP-3284467-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2019-10-30 | — | — | EP | claimed |
| EP-3328383-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | Attenua, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| EP-2566476-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2017-11-22 | — | — | EP | claimed |
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. | 2017-09-28 | — | — | US | claimed |
| WO-2017023700-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-20110274628-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011139811-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. (US) | 2011-11-10 | — | — | WO | claimed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| EP-4281065-A1 | ENHANCEMENT OF CAMP SIGNALING AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF DEPRESSION AND RELATED CONDITIONS | Alto Neuroscience, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-4281056-A1 | COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION- RELATED DYSFUNCTION EXISTS | Alto Neuroscience, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2013002365-A1 | ANTIPRURITIC AGENT | 東レ株式会社 (JP) | 2013-01-03 | — | — | WO | disclosed |
| US-20110274628-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. | 2011-11-10 | — | — | US | disclosed |
| WO-2011139811-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011036167-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | CHRNA7 4/4885 |
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885 |
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | CHRNA7, CHRNA3, CHRNA6 | CHRNA7 1/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CHRNA7 83/4885 |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.